On June 17, the Korea Biotechnology Industry Organization (KoreaBIO) and BXPLANT will host the “Preclinical and Clinical Development Boot Camp: Bio Bridge,” a comprehensive program designed to support bio companies in achieving successful commercialization and establishing robust clinical trial strategies.
Program Overview
Bio Bridge targets bio companies preparing to enter preclinical or clinical trials, as well as those facing challenges in formulating technology commercialization strategies post-entry. Participating companies will receive intensive training on comprehensive preclinical and clinical development strategies, complemented by personalized 1:1 expert consulting tailored to each company’s specific needs.
The boot camp curriculum covers practical, field-oriented development strategies including:
▸ Clinical development strategy for successful new drug development
▸ Preclinical R&D strategy establishment
▸ Clinical pharmacology (PK/PD/ADME)
▸ PK simulation strategy for preclinical-to-clinical transition
▸ Early clinical development fundamentals
▸ Securing clinical Proof of Concept (PoC)
▸ Global clinical operations strategy
Additionally, participating companies will have access to on-site individual consulting sessions with industry experts.
Leadership Perspectives
“The Bio Bridge program systematically addresses the strategic challenges that bio companies encounter throughout the entire development cycle—from initial preclinical stages through clinical entry and technology commercialization,” stated Soo Jung Park, Director of the Member Support Center at KoreaBIO. “Our core objective is to enable more efficient and successful development strategies through expert-led practical training and company-specific consulting.”
Minkeun Jo, CEO of BXPLANT, emphasized, “Preclinical and clinical development are the most critical phases in determining the potential and value of innovative research and technology ventures. Through this program, we are committed to analyzing the diverse risk factors inherent in the preclinical and clinical development process and delivering customized solutions.”
Registration Information
Companies interested in participating may register through the Korea Biotechnology Industry Organization website by 16:00 on June 13. For additional details and application procedures, please visit the KoreaBIO website.
All sessions will be conducted in Korean only.
